Market Position

Therapeutic Antibodies

MorphoSys is, and has been, active in this dynamic, rapidly growing market for several years, and is thus strategically well placed to exploit this growth. The unique features of the MorphoSys technology, which enables the creation of tailor-made antibody drugs, are expected to increase the probability of development success. This is a key factor in explaining why the technology is so highly regarded in the pharmaceutical industry.

Today, the majority of the top 20 pharmaceutical companies work with MorphoSys’s technologies to discover and develop new antibody drugs. MorphoSys has thereby achieved one of the goals the Company set itself several years ago, namely to become the partner of choice for pharmaceutical companies developing antibody drugs.

Research Antibodies

MorphoSys’s Research Antibodies segment operating under the brand “Antibodies by Design” was launched in 2003. The aim of this segment was to further develop the market for non-therapeutic applications. In 2005, MorphoSys announced the acquisition of the U.K. and U.S.-based Biogenesis Group, a supplier of antibodies to the life sciences research community. The acquisition provided MorphoSys with immediate access to new market channels for its HuCAL technology. In line with this strategy, MorphoSys acquired the Serotec Group in January 2006. Serotec was one of the top three research antibody suppliers in Europe.

Today, MorphoSys’s AbD - Antibodies Direct unit is a leading antibody supplier in Europe and among the top 20 companies worldwide in this field.